A Silicon Valley start-up with some big-name backers is threatening to upend genetic screening for breast andovarian cancer by offering a test on a sample of saliva that is so inexpensive that most women could get it.
At the same time, the nation’s two largest clinical laboratories, Quest Diagnostics and LabCorp, normally bitter rivals, are joining with French researchers to pool their data to better interpret mutations in the two mainbreast cancer risk genes, known as BRCA1 and BRCA2. Other companies and laboratories are being invited to join the effort, called BRCA Share.
And some men and women faced a far greater risk, a team at the Institute of Cancer Research in London said.
Cancer Research UK suggested drugs targeted at breast cancer may work in some lung cancers.
The links between variants of the BRCA genes and breast cancer are well established – a diagnosis led Hollywood actress Angelina Jolie to have a preventative double mastectomy – but it has also been linked with an increased risk of other cancers affecting women such as ovarian cancer and prostate cancer in men.